FDA Approves Pfizer's Palbociclib Combo for Metastatic Breast Cancer Maintenance
Tom Rudovsky · Reported by Reuters
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment
Positive
Importance
8
Price
$24.245
Mkt Cap
$138.183B
52W Low
$23.11
52W High
$28.745
52W Position
4.9% above low
Off High
16% below high
Rel. Volume
0.7× avg
Market data snapshot near publication time
PFE is trading near its 52-week low of $23.11 (4.9% above the low).
Summary
The FDA has approved Pfizer's Palbociclib combination therapy for the maintenance treatment of HR-positive, HER2-positive metastatic breast cancer. This expands the label for Palbociclib, an existing key oncology drug, into a new patient population. The approval strengthens Pfizer's oncology portfolio and offers new revenue potential from an established product.
At the time of this announcement, PFE was trading at $24.25 on NYSE in the Life Sciences sector, with a market capitalization of approximately $138.2B. The 52-week trading range was $23.11 to $28.75. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.
Price Chart
PFE - Latest Insights
PFE
Oct 01, 2026, 3:00 AM EDT
Price at Filing:
$28.59
Real-time Price:
$28.41
Change:
-$0.180 (-0.63%)
Market Cap:
$162.555B
PFE
Oct 01, 2026, 2:30 AM EDT
Price at Filing:
$28.59
Real-time Price:
$28.41
Change:
-$0.180 (-0.63%)
Market Cap:
$162.555B
PFE
Sep 21, 2026, 2:15 AM EDT
Price at Filing:
$27.62
Real-time Price:
$28.41
Change:
+$0.790 (+3%)
Market Cap:
$162.555B
PFE
Sep 07, 2026, 2:46 AM EDT
Price at Filing:
$28.44
Real-time Price:
$28.41
Change:
-$0.030 (-0.11%)
Market Cap:
$162.555B
PFE
Aug 27, 2026, 4:30 PM EDT
Price at Filing:
$28.05
Real-time Price:
$28.41
Change:
+$0.360 (+1%)
Market Cap:
$162.555B